ACXP — Acurx Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1736243 ·
Last close
$1.50
Market Cap
$6.45M
52W High
$3.18
52W Low
$1.34
ADV30
83,300
Next earnings
2026-08-14
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,715,990 | -1,680,982 | 9,539,952 | 9,254,813 | 2,526,809 |
| Dec 2025 | 0 | — | -1,617,116 | -1,578,276 | 7,689,535 | 7,556,100 | 2,420,943 |
| Sep 2025 | 0 | — | -2,028,701 | -1,992,790 | 6,105,211 | 5,906,802 | 2,468,175 |
| Jun 2025 | 0 | — | -2,269,683 | -2,246,279 | 6,157,858 | 6,064,128 | 2,591,527 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,143,816
Investing CF
—
Financing CF
$10,754,742
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-5.89
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-75,288,494
Inventory
—
Receivables
$48,417
ST Investments
—
EBIT TTM
$-8,064,693
Pretax Income TTM
$-7,966,538
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,091,983 | -7,966,538 | 7,689,535 | 2,420,943 | — | -6,787,782 |
| Dec 2024 | 0 | -14,123,227 | -14,103,103 | 3,857,963 | 3,242,842 | — | -10,383,431 |
| Dec 2023 | 0 | -14,577,768 | -14,577,768 | 7,709,123 | 3,042,438 | — | -9,800,885 |
| Dec 2022 | 0 | -12,092,776 | -12,092,776 | 9,376,706 | 2,061,685 | — | -7,542,290 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.13
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SILO | Silo Pharma, Inc. | $6.43M | $5.70 | — |
| CURX | Curanex Pharmaceuticals Inc | $6.31M | $0.22 | — |
| PULM | Pulmatrix, Inc. | $6.28M | $1.72 | — |
| XBIO | Xenetic Biosciences, Inc. | $6.27M | $2.73 | — |
| GOVX | GeoVax Labs, Inc. | $6.15M | $1.18 | — |
News headlines (Yahoo Finance, 1h cache)
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
2026-07-08 12:00 · Yahoo
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Developmen
2026-06-16 12:00 · Yahoo
Acurx Pharmaceuticals (ACXP) Upgraded to Buy: Here's Why
2026-06-08 16:00 · Yahoo
Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat
2026-05-19 16:25 · Yahoo
Acurx Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary
2026-05-12 17:05 · Yahoo
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
2026-05-12 11:01 · Yahoo
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026
2026-05-04 12:00 · Yahoo
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
2026-04-29 12:00 · Yahoo
Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit
2026-04-27 12:00 · Yahoo
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
2026-04-20 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.